Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform

Biochemical and Biophysical Research Communications

Volumn 309, Issue 1, 2003, Pages 18-25

  Shiwa, Mieko ^a   Nishimura, Yumiko ^b   Wakatabe, Rumi ^a   Fukawa, Ai ^a   Arikuni, Hisashi ^c   Ota, Hiroyuki ^d   Kato, Yo ^e   Yamori, Takao ^b  

^a Yokohama Bus Park East Tower 14F   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c SC Bioscience KK   (Japan)

^d CANCER INSTITUTE   (Japan)

^e CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Biomarker; Colon cancer; Expression Difference Mapping; ProteinChip; RC MS; SELDI

Indexed keywords

PROTHYMOSIN ALPHA; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; GENE MAPPING; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEOMICS; TANDEM MASS SPECTROMETRY; TISSUE SPECIFICITY;

EID: 0042736304     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01520-1     Document Type: Article

References (37)

1. Mitchell E.P. Role of carcinoembryonic antigen in the management of advanced colorectal cancer. Semin. Oncol. 25:1998;12-20.
2. Schmoll H.J., Beyer J. Prognostic factors in metastatic germ cell tumors. Semin. Oncol. 25:1998;174-185.
3. Bartlett N.L., Freiha F.S., Torti F.M. Serum markers in germ cell neoplasms. Hematol. Oncol. Clin. North Am. 5:1991;1245-1260.
4. Osterling J.E. Prostate specific antigen a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145:1991;907-923.
5. Hutchens T.W., Yip T.T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid. Commun. Mass Spectrom. 7:1993;576-580.
6. Vlahou A., Schellhammer P.F., Medrinos S., Kondylis F.I., Gong L., Nasim S., Wright G.L. Jr. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158:2001;1491-1501.
7. Petricoin E.F., Ornstein D.K., Paweletz C.P., Ardekani A., Hackett P.S., Hitt B.A., Velassco A., Trucco C., Wiegand L., Wood K., Simone C.B., Levine P.J., Linehan W.M., Emmert-Buck M.R., Steinberg S.M., Kohn E.C., Liotta L.A. Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 94:2002;1576-1578.
8. Qu Y., Adam B.-L., Yasui Y., Ward M.D., Cazares L.H., Schellhammer P.F., Feng Z., Semmes O.J., Wright G.L. Jr. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin. Chem. 48:2002;1835-1843.
9. Cazares L.H., Adam B.-L., Ward M.D., Nasim S., Schellhammer P.F., Semmes O.J., Wright G.L. Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin. Cancer Res. 8:2002;2541-2552.
10. Adam B., Qu Y., Davis J.W., Ward M.D., Clements M.A., Cazares L.H., Semmens O.J., Schellhammer P.F., Yasui Y., Ziding F., Wright G. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62:2002;3609-3614.
11. Liotta L.A., Petricoin III E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C. General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol. Oncol. 88:2003;S25-S28.
12. Bandera C.A., Ye B., Mok S.C. New technologies for the identification of markers for early detection of ovarian cancer. Curr. Opin. Obstet. Gynecol. 15:2003;51-55.
13. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., Mills G.B., Simone C., Fishman D.A., Kohn E.C., Liotta L.A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577.
14. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approached for identification of serum biomarkers to detecting breast cancer. Clin. Chem. 48:2002;1296-1304.
15. Paweletz C.P., Trock B., Pennanen M., Tsangaris T., Magnant C., Liotta L.A., Petricoin III E.F. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers. 17:2001;301-307.
16. Carter D., Douglass J.F., Cornellison C.D., Retter M.W., Johnson J.C., Bennington A.A., Fleming T.P., Reed S.G., Houghton R.L., Diamond D.L., Vedvick T.S. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry. 41:2002;6714-6722.
17. Poon T.C.W., Yip T.T., Chan A.T.C., Yip C., Yip V., Mok T.S.K., Lee C.C.Y., Leung T.W.T., Ho S.K.W., Johnson P.J. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin. Chem. 49:2003;752-760.
18. Zhukov T.A., Johanson R.A., Cantor A.B., Clark R.A., Tockman M.S. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer. 40:2003;267-279.
19. Yip T.T., Lomas L. Technol. Cancer Res. Treat. 1:2002;273-280.
20. Wulfkuhle J.D., Liotta L.A., Petricoin E.F. Proteomic applications for the early detection of cancer. Nat. Rev. 3:2003;267-272.
21. Srinivas P.R., Verma M., Zhao Y., Srivastava S. Proteomics for cancer biomarker discovery. Clin. Chem. 48:2002;1160-1169.
22. Rosty C., Christa L., Kuzdzal S., Baldwin W.M., Zahurak M.L., Carnot F., Chan D.W., Canto M., Lillemoe K.D., Cameron J.L., Yeo C.J., Hruban R.H., Goggins M. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 62:2002;1868-1875.
23. Weinberger S.R., Boschetti E., Santambien P., Brenac V. Surface-enhanced laser desorption-ionization retentate chromatography mass spectrometry (SELDI-RC-MS): a new method for rapid development of process chromatography conditions. J. Chromatogr. B. 782:2002;307-316.
24. Yamori T., Matsunaga A., Sato S., Yamazaki K., Komi A., Shizu K., Mita I., Edatsugi H., Matsuba Y., Takezawa K., Nakanishi O., Kohno H., Nakajima Y., Komatsu H., Andoh T., Tsuruo T. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by in vitro and in vivo human cancer cell line panel. Cancer Res. 59:1999;4042-4049.
25. Dan S., Tsunoda T., Kitahara O., Yanagawa R., Zembutsu H., Katagiri T., Yamazaki K., Nakamura Y., Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62:2002;1139-1147.
26. Chapman K. The ProteinChip® Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation Biochem. Soc. Trans. 30:2002;82-87.
27. Zhang L., Yu W., He T., Yu J., Caffrey R.E., Dalmasso E.A., Fu S., Pham T., Mei J., Ho J.J., Zhang W., Lopez P., Ho D.D. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science. 298:2002;995-1000.
28. Davies H., Lomas L., Austen B. Profiling of amyloid beta peptide variants using SELDI ProteinChi® Arrays BioTechniques. 27:1999;1258-1262.
29. Bane T.K., LeBlanc J.F., Lee T.D., Riggs A.D. DNA affinity capture and protein profiling by SELDI-TOF mass spectrometry: effect of DNA methylation. Nucleic Acids Res. 30:2002;e69.
30. Melamed P., Koh M., Preklathan P., Bei L., Hew C. Multiple mechanisms for Pitx-1 transactivation of a luteinizing hormone subunit gene. J. Biol. Chem. 277:2002;26200-26207.
31. Spencer D., Robson L., Purdy D., Whitelegg N.R., Michael N.P., Bhatia J., Sharma S., Rees A., Minton N.P., Begent R.H.J., Chester K. A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics. 2:2002;271-279.
32. Weinberger S.R., Viner R.I., Ho P. Tagless extraction-retentate chromatography: a new global protein digestion strategy for monitoring differential protein expression. Electrophoresis. 23:2002;3182-3192.
33. Reid G., Gan B.S., She Y.M., Ens W., Weinberger S., Howard J.C. Rapid identification of probiotic lactobacillus biosurfactant proteins by ProteinChip® tandem mass spectrometry tryptic peptide sequencing Appl. Environ. Microbiol. Feb. 2002;977-980.
34. Wang J.Y., Tang R., Chiang J.M. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis. Colon Rectum. 37:1994;272-277.
35. Haritos A.A., Goodall G.J., Horecker B.L. Prothymosin alpha: isolation and proaties of the major immunoreactive form of thymosin alpha1 in rat thymus. Proc. Natl. Acad. Sci. USA. 81:1984;1008-1011.
36. Dies M., Cerdan F.J., Pollan M., Maestro M.L., Ortega M.D., Martinez S., Moreno G., Balibrea J.L. Prognostic significance of reoperative serum CA19.9 assay in patients with colorectal carcinoma. Anticancer Res. 14:1994;2819-2825.
37. Mori M.M., Barnard G.F., Staniunas R.J., Jessu M., Steele G.D. Jr., Chen L.B. Prothymosin-α mRNA expression correlates with that of c-myc in human colon cancer. Oncogene. 8:1993;2821-2826.